Pharmafile Logo

Souvenaid

- PMLiVE

Roche’s spinal muscular atrophy therapy recommended by CHMP for newborns

Evrysdi is already approved in the EU to treat SMA patients aged two months or older

- PMLiVE

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

The long-term inflammatory skin condition affects an estimated 1% of the global population

- PMLiVE

PMEA welcome Stephanie Hall as new chair

The founder and CEO of Uptake has been taking part in the judging process for seven years

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by CHMP for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

- PMLiVE

Merck granted positive CHMP opinion for Keytruda combination in gastric cancer

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Janssen receives positive CHMP opinion for Talvey in multiple myeloma

More than 50,900 people in Europe were diagnosed with multiple myeloma in 2020

- PMLiVE

Continuing Medical Education Outcomes are Much More Than Statistical Significance

At Medscape Education, we hold ourselves to the highest standards when it comes to analysing our programs. Our approach is unparalleled, employing a precise paired method that ensures we measure the...

Medscape Education

- PMLiVE

So, you can deliver excellent outcomes & meaningful impact at low cost

Under the tree: an example of behaviour-change in mental health by fox&cat.

Fox&Cat

- PMLiVE

The Most Important Person in the Room—A Look at Patient -Centricity at EHA

Across all of healthcare, a greater focus is being placed on patient centricity in order to improve outcomes and enhance patients’ quality of life. Although patient centricity is necessary in...

Medscape Education

- PMLiVE

Roche partners with Alnylam on hypertension therapy in deal worth up to $2.8bn

Zilebesiran is in phase 2 development to treat hypertension in patients with high-unmet needs

- PMLiVE

Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Johnson & Johnson sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for a selected group of medicines

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links